GlyPeB: Dermal Substitution in Pediatric Burns

Sponsor
Radboud University Medical Center (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05309720
Collaborator
(none)
20
42.1

Study Details

Study Description

Brief Summary

The standard treatment of deep dermal to full thickness burns is surgical removal of the burn followed by skin transplantation. Dermal substitutes are increasingly used in the treatment of deep burns to replace lost dermis. Preservation of the collagen and elastin in the acellular human dermal substitute Glyaderm provides a more elastic scar. It is unknown what the effect of Glyaderm on scar quality is in a solely paediatric population.

The objective of this case series is to investigate scar maturation and scar quality when applying Glyaderm in deep dermal to full thickness burns in a pediatric population aged ≤15 years old.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Glyaderm
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
prospective case seriesprospective case series
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Dermal Substitution in Paediatric Burns: A Prospective Case Series
Anticipated Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
Nov 1, 2025
Anticipated Study Completion Date :
Nov 1, 2025

Outcome Measures

Primary Outcome Measures

  1. Scar quality (clinician) [12 months]

    Scar quality measured using the Patient and Observer Scar Assessment Scale (POSAS) Observer Scale, which rates the scar from 1 (=like normal skin) to 10 (=worst scar imaginable).

Secondary Outcome Measures

  1. Clinical assessment of the graft take [5-7 days after STSG application]

    Take of the split thickness skin graft (STSG) in percentages. The take is defined as STSG that appears vital and is adherent to the wound bed.

  2. Wound epithelialization [5-7 days after STSG application]

    Wound epithelialization is the percentage of the graft with a vital skin graft and healed graft interstices.

  3. Wound healing time [determined in the first several days to weeks after STSG application]

    >95% epithelialization of the wound area is considered as healed

  4. Donor site healing time [determined in the first several days to weeks after STSG application]

    >95% epithelialisation of the donor site wound surface area is considered as healed

  5. Scar surface area [day of surgery (day 0) and 3, 6 and 12 months post-surgery]

    The scar surface area is calculated using the surgery wound as reference area

  6. Scar quality (participant) [3, 6 and 12 months post-surgery]

    Scar quality measured using the Patient and Observer Scar Assessment Scale (POSAS) Patient Scale, rating the scar from 1 (=like normal skin) to 10 (=worst scar imaginable).

  7. Occurrence of scar contractures [Up to 12 months post-surgery]

    Scar contractures often occur in children with deep dermal and full thickness burn wounds.

  8. Occurrence of scar hypertrophy [Up to 12 months post-surgery]

    Scar hypertrophy often occurs in children with deep dermal and full thickness burn wounds.

  9. Range of motion of affected joints [3, 6 and 12 months post-surgery]

    When joints are affected due to the burn wound, the range of motion of the affected joint(s) will be monitored during follow-up.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 15 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age ≤15 years old

  2. Burn wounds requiring skin grafting

  3. Written informed consent provided by

  4. The participant's parent(s)/guardian (<12 years of age)

  5. The participant's parent(s)/guardian and the participant itself (12-15 years old)

Exclusion Criteria:
  1. Burn wound of ≤30 cm2

  2. Infected burn wounds: clinical symptoms in combination with positive wound swabs

  3. Patients/parents with insufficient knowledge of the Dutch or English language, since they would not be able to complete the POSAS questionnaire.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Radboud University Medical Center

Investigators

  • Principal Investigator: Marielle Vehmeijer-Heeman, MD, PhD, Radboud University Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Radboud University Medical Center
ClinicalTrials.gov Identifier:
NCT05309720
Other Study ID Numbers:
  • 2022-13625
First Posted:
Apr 4, 2022
Last Update Posted:
Apr 4, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Radboud University Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 4, 2022